GLP-1glp-1 receptor agonistsatrial fibrillationtype 2 diabetesstroke

Danish registry links GLP-1 use to lower stroke rate in atrial fibrillation

Among 15,914 matched adults with both atrial fibrillation and type 2 diabetes, users also had lower all-cause mortality and fewer hospitalisations.

By Maren Holt · Senior Reporter, GLP-1

Oct 8 03:36 ETSource: European Medical Journal

The wire

01Danish nationwide registry data from 2010-2023 matched 7,957 GLP-1 receptor agonist initiators 1:1 with non-users; 642 strokes occurred, with an adjusted hazard ratio of 0.65 (95% CI 0.59-0.77) for users.
02Clinicians managing overlapping arrhythmic and metabolic risk now have population-level signal that incretin benefits may extend to patients with atrial fibrillation.
03Authors stress the findings are observational and should not alter oral anticoagulation decisions, which remain central to stroke prevention in eligible atrial fibrillation patients.

From the source

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Stroke in Patients with Atrial Fibrillation and Type 2 Diabetes: A Danish Nationwide Cohort Study
This site is intended for healthcare professionals

Read at emjreviews.com

Source URL https://www.emjreviews.com/cardiology/abstract/glucagon-like-peptide-1-receptor-agonists-and-the-risk-of-stroke-in-patients-with-atrial-fibrillation-and-type-2-diabetes-a-danish-nationwide-cohort-study-j02126/